A multibillion corporation headquartered in Saudi Arabia has a venture arm that invests in healthcare. The firm started as an end-to-end logistics and commercialization partner for healthcare products (including pharmaceuticals and medical devices) mainly for global blue chips, with manufacturing facilities in partnership with large corporations. The corporation’s venture arm will be contributing to investments in biotech companies in Series A and later stage companies.

Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics  and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms.

Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines.

The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Japan manages a fund dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market.

The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond.

The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in the US invests in early-stage opportunities to translate key insights in human biology into viable therapeutics. The firm believes that no target is “undruggable” – rather, it is currently “undone”.  The firm is open to sharing expertise in developing comprehensive chemical equity strategies and their “whatever it takes” mindset to identify high-quality candidates for clinical proof-of-concept. The firm makes investments ranging from $1-10M in Series A companies focusing in the U.S. and Europe.

The firm focuses mostly on therapeutics  in pre-clinical and clinical stages and is drawn to the compelling targets which have emerged from population-wide genetic association studies, where human loss-of-function mutations point to an inhibitor strategy, and gain-of-function mutations provide a gene dose-response. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm s looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2020, a life science venture capital arm of a large corporation is interested in therapeutic, medical device, diagnostic, and digital health technologies. The firm usually participates in Seed to series C financing rounds with check sizes between $500K – 2M USD. The firm is open to both leading and co-investing and is aiming to make 15 investments in the next 12 months. The firm is open to global opportunities.

The firm is open to considering innovative technologies that address unmet medical needs in therapeutics, diagnostics, medical devices, and digital health. The firm’s greatest interest lies in the biotech and diagnostic sector in which the firm have the strongest expertise. For medical devices and diagnostics, the firm is open to any subsectors but is most interested in AI-based diagnostics and innovative genomics applications.  The firm is open to any indication area including oncology, CNS diseases and rare diseases.

The firm seeks to work with companies with a sound business model and great execution, but will mainly focus on the merit of technologies and the team when working with very early-stage companies. The firm considers itself to be an active investor and will take a board seat depending on the cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2018, a healthcare and life sciences focused venture capital firm with USA and China offices manages $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.

The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.

The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2018 with headquarters in the US closed an initial fund of $20M USD dedicated to early-stage life science ventures from Pre-seed to Seed. The initial size of investment ranges from $250k-1M. The firm partners with companies in the US, Canada, UK, and Israel.

The firm is interested in companies under a $50M valuation cap. The firm acts as a co-investor and will not require board seating.

The firm is interested in deep health-tech. The firm is opportunistic and will consider pre-FDA companies in development and clinical phases. The firm is not interested in traditional pharmaceuticals, diagnostics, or health information technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Canada was co-founded by a physician who previously co-founded a successful private equity firm. The firm is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD 0.5 million and USD 5 million. The firm is currently operating out of its second fund. The firm participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel.

The firm is primarily interested in investing in companies in the digital health sector but will also consider the medical and diagnostic devices sectors that have a digital component to them. The firm is open to all modalities within the digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in development as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology to be revenue generating.

The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat as determined by check size on a case-by-case basis. The firm will participate both as a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.